Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies (Q33412490)

26 July 2017

Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies (English)

1 reference

26 July 2017

1 reference

ChEBI release 2020-05-28

1 reference

Sandrine Faivre

2

0 references

author name string

Francois Goldwasser

1

1 reference

26 July 2017

Jerome Alexandre

3

1 reference

26 July 2017

Cinthya Coronado

4

1 reference

26 July 2017

Eva M Fernández-García

5

1 reference

26 July 2017

Carmen M Kahatt

6

1 reference

26 July 2017

Pilar García Paramio

7

1 reference

26 July 2017

Jorge Luis Iglesias Dios

8

1 reference

26 July 2017

Bernardo Miguel-Lillo

9

1 reference

26 July 2017

Eric Raymond

10

1 reference

26 July 2017

7 January 2014

1 reference

Investigational New Drugs

26 July 2017

1 reference

26 July 2017

32

1 reference

26 July 2017

3

1 reference

26 July 2017

500-509

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-013-0060-7

26 July 2017

0 references

cites work

Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0060-7

Cancer treatments: can we find treasures at the bottom of the sea?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0060-7

Levels of SCS7/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor PM02734.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0060-7

Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0060-7

PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0060-7

Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0060-7

A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0060-7

Complete and sustained objective response per RECIST to Irvalec (PM02734) in undifferentiated large cell esophageal adenocarcinoma: A case report and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0060-7

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0060-7

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0060-7

Kahalalide F and ES285: potent anticancer agents from marine molluscs.

21 January 2018

1 reference

12 December 2020

Kahalalides: Bioactive Peptides from a Marine Mollusk Elysia rufescens and Its Algal Diet Bryopsis sp.(1)

1 reference

12 December 2020

Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors

1 reference

12 December 2020

ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines

1 reference

12 December 2020

Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM02734, a novel antineoplastic agent, in dog plasma

1 reference

12 December 2020

Accelerated titration designs for phase I clinical trials in oncology

1 reference

12 December 2020

10.1007/S10637-013-0060-7

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference